Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

Part of paid clinical trials in Brownsville, Texas.

Sponsor
The University of Texas Health Science Center, Houston
Study ID
NCT05119179
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • PreDiabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Glucagon-like Peptide 1 Receptor Agonist

Study Details

This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will illuminate causal links between disease genotype and phenotype, which may ultimately guide personalized therapeutic approaches for type 2 diabetes, prediabetes, obesity, cardiovascular disease, renal disease, and other related diseases.

Key Dates

Start date
Nov 22, 2021
Status verified
Mar 2026
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
300 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    Semaglutide 0.25 mg subcutaneously weekly for 4 weeks, followed by semaglutide 0.5 mg subcutaneously weekly for 8 weeks.

Primary Outcome Measure

Mean change in beta cell responsivity [ Time Frame: 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UTHealth Clinical Research Unit (CRU) at UT BrownsvilleBrownsvilleTexas78520
Norma Perez-Olazaran
[email protected]
956-755-0695
Rocio Uribe
[email protected]
(956) 882-5165

Find similar trials in Brownsville, TX

By research site
UTHealth Clinical Research Unit (CRU) at UT Brownsville· Brownsville, TX

Related Studies